Nuvectra Corporation, a neuromodulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. It operates through two segments, Nuvectra and NeuroNexus. The company offers Algovita spinal cord stimulation system that is used for the treatment of chronic pain of the trunk and limbs. It also designs, manufactures, and sells neural interface technologies, including microelectrode arrays, custom designed probes, and electrode instrumentation and accessories; and develops Virtis, a sacral neuromodulation system for the treatment of chronic urinary retention and overactive bladder. The company serves hospitals, surgery centers, and medical facilities through a direct sales force and third-party distributors in the United States and Europe. Nuvectra Corporation was founded in 2008 and is headquartered in Plano, Texas.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVTR
Previous SymbolNASDAQ:NVTRV
CUSIPN/A
Phone214-474-3103
Debt
Debt-to-Equity Ratio0.42
Current Ratio7.63
Quick Ratio7.35
Price-To-Earnings
Trailing P/E Ratio-4.25
Forward P/E Ratio-5.37
P/E GrowthN/A
Sales & Book Value
Annual Sales$31.84 million
Price / Sales9.91
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.47 per share
Price / Book4.01
Profitability
EPS (Most Recent Fiscal Year)($4.22)
Net Income$-44,600,000.00
Net Margins-87.94%
Return on Equity-65.86%
Return on Assets-36.96%
Miscellaneous
Employees195
Outstanding Shares17,610,000
Market Cap$315.55 million
OptionableOptionable
Nuvectra (NASDAQ:NVTR) Frequently Asked Questions
What is Nuvectra's stock symbol?
Nuvectra trades on the NASDAQ under the ticker symbol "NVTR."
How were Nuvectra's earnings last quarter?
Nuvectra Corp (NASDAQ:NVTR) announced its earnings results on Monday, October, 29th. The company reported ($0.87) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.86) by $0.01. The company earned $14.22 million during the quarter, compared to the consensus estimate of $12.38 million. Nuvectra had a negative net margin of 87.94% and a negative return on equity of 65.86%. View Nuvectra's Earnings History.
When is Nuvectra's next earnings date?
What price target have analysts set for NVTR?
4 brokerages have issued 12-month price targets for Nuvectra's shares. Their forecasts range from $21.00 to $27.00. On average, they anticipate Nuvectra's stock price to reach $24.00 in the next year. This suggests a possible upside of 33.9% from the stock's current price. View Analyst Price Targets for Nuvectra.
What is the consensus analysts' recommendation for Nuvectra?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvectra in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nuvectra.
Has Nuvectra been receiving favorable news coverage?
News stories about NVTR stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Nuvectra earned a daily sentiment score of 0.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days.
Who are some of Nuvectra's key competitors?
Some companies that are related to Nuvectra include Nevro (NVRO), AtriCure (ATRC), K2M Group (KTWO), Orthofix Medical (OFIX), Cryolife (CRY), Cardiovascular Systems (CSII), Tactile Systems Technology (TCMD), Intersect ENT (XENT), AngioDynamics (ANGO), SurModics (SRDX), OraSure Technologies (OSUR), Cerus (CERS), LeMaitre Vascular (LMAT), Antares Pharma (ATRS) and SI-Bone (SIBN).
Who are Nuvectra's key executives?
Nuvectra's management team includes the folowing people:
- Mr. Scott F. Drees, CEO & Director (Age 60)
- Mr. Joseph Paul Hanchin, Pres (Age 56)
- Mr. Walter Z. Berger, COO, CFO & Exec. VP (Age 62)
- Ms. Jennifer J. Kosharek, VP, Controller & Principal Accounting Officer (Age 37)
- Mr. Benjamin Tranchina, Chief Technology Officer
Who are Nuvectra's major shareholders?
Nuvectra's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.43%), Dimensional Fund Advisors LP (4.23%), Vanguard Group Inc. (3.85%), Peregrine Capital Management LLC (4.19%), Russell Investments Group Ltd. (3.79%) and Rockefeller Capital Management L.P. (2.45%). Company insiders that own Nuvectra stock include Joseph A Miller, Joseph Paul Hanchin, Scott F Drees, Thomas Edward Zelibor and Thomas Kelley Hickman. View Institutional Ownership Trends for Nuvectra.
Which major investors are selling Nuvectra stock?
NVTR stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Hodges Capital Management Inc., JPMorgan Chase & Co., Perceptive Advisors LLC, Laurel Wealth Advisors Inc., Raffles Associates LP and TIAA CREF Investment Management LLC. View Insider Buying and Selling for Nuvectra.
Which major investors are buying Nuvectra stock?
NVTR stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Point72 Asset Management L.P., Russell Investments Group Ltd., AWM Investment Company Inc., Falcon Point Capital LLC, Northpointe Capital LLC, BlackRock Inc. and Monashee Investment Management LLC. Company insiders that have bought Nuvectra stock in the last two years include Joseph A Miller, Scott F Drees and Thomas Edward Zelibor. View Insider Buying and Selling for Nuvectra.
How do I buy shares of Nuvectra?
Shares of NVTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nuvectra's stock price today?
One share of NVTR stock can currently be purchased for approximately $17.92.
How big of a company is Nuvectra?
Nuvectra has a market capitalization of $315.55 million and generates $31.84 million in revenue each year. The company earns $-44,600,000.00 in net income (profit) each year or ($4.22) on an earnings per share basis. Nuvectra employs 195 workers across the globe.
What is Nuvectra's official website?
How can I contact Nuvectra?
Nuvectra's mailing address is 5830 GRANITE PKWY SUITE 1100, PLANO TX, 75024. The company can be reached via phone at 214-474-3103 or via email at [email protected]
MarketBeat Community Rating for Nuvectra (NASDAQ NVTR)
MarketBeat's community ratings are surveys of what our community members think about Nuvectra and other stocks. Vote "Outperform" if you believe NVTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
